Dr Reddy's is mulling a buyback of equity shares.
Explaining the rationale behind the move Saumen Chakraborty, President and CFO, Dr Reddy's Lab said they will be making a proposal to the board on February 17 and as per listing obligation and disclosure requirement they have notified to the stock exchanges.
However, he said it would not be right to disclose beforehand what the company will propose in the board meeting.
With regards to cash he said as declared during the results earlier we had a small debt but at the end of Q3, it has turned to net cash. We have Rs 447 crore of net cash surplus. However, total cash availability will definitely.
With regards to USFDA concerns, he said the company has given a comprehensive response to the warning letter of December 7 and given an update on progress of remediation in last week of January.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!